Russian vaccine 'passes preliminary test'


According to research published in The Lancet Friday, patients involved in the initial tests of the Russian coronavirus vaccine developed antibodies with "no serious adverse events", but experts say that these cases are too strong to prove safety and effectiveness. Were few

Russian vaccine 'passes preliminary test'


Russia announced last month that its vaccine, known as the "Sputnik V", had already been approved’ after the Soviet-era satellite was first launched into space in 1957.

This has raised concerns among Western scientists about the lack of safety data, with some warning that moving too fast on a vaccine could be dangerous.

Russia denounced the criticism as an attempt to undermine Moscow's research.

The trials were open-label and not randomized, meaning there was no placebo and participants knew they were receiving the vaccine and were not randomly assigned’ to different treatment groups.

The researchers stressed that larger and longer trials - including placebo comparisons - would be needed to establish the long-term safety and efficacy of the vaccine to prevent Covid 19 infections.

The report said 76 participants in the trials would be monitored’ for 180 days, adding that "more rigorous Phase 3 clinical trials involving 40,000 volunteers from different age and risk groups." The trial was, planned.

- 'Safety is paramount' -.

Naor Bar-Zeev of the Johns Hopkins Bloomberg School of Public Health, who did not participate in the study, said the research was "encouraging but small", adding that it had no data on the effectiveness in older groups. Given, who are particularly at risk. Covid-19

"Safety with the Covid 19 vaccine will be crucial, not only for vaccine acceptance but also for widespread confidence in vaccination," he said in a comment in the Lancet.

"Because healthy people are vaccinated and, during the Cove 19 epidemic, possibly after everyone has been approved after Phase 3 trials, safety is very important."

The epidemic has seen unprecedented mobilization of funds and research to rush through a vaccine that could protect billions of people around the world.

This week, the United States urged states to prepare for the elimination of the vaccine two days before the November presidential election, which has raised concerns that President Donald Trump's administration has set a political timetable. Accelerating research to fit.

Russia says industrial production of its version is expected’ from September.

President Vladimir Putin said in early August that the vaccine provided "permanent immunity" and that one of his own daughters had been vaccinated’ although Russia's health ministry said clinical trials were not yet complete. Were

The World Health Organization (WHO) has urged Russia to adhere to the guidelines it has established and to "go through all the steps" to develop a safe vaccine.

The Sputnik V was developed in collaboration with the Russian Ministry of Defense by the Gamaleya Research Institute for Infectious Diseases and Microbiology in Moscow.

It uses the cold-causing adenovirus, which has since been replaced’ with a portion of the new Corona virus, SARS-CoV-2.

Denis Logunov Gamaleya, lead author of the report, said the adenovirus vaccine enters human cells and provides the SARS-KO-2 spike protein genetic code, which allows the immune system to "recognize and attack" the virus. Helps to

In the Lancet study, Russian researchers conducted two small trials, each involving 38 healthy adults between the ages of 18 and 60, who were vaccinated’ in two doses.

Each participant was given’ a dose of the first dose of the vaccine and then a booster with the second dose 21 days later.

They were monitored’ for more than 42 days and all antibodies were ready within the first three weeks.

Statistics show that the vaccine was "safe, well-tolerated, and does not cause serious adverse events in healthy adult volunteers," the report said.


READ MORE 

Trump mocks Biden for wearing mask, rejects health questions at Pennsylvania rally

Post a Comment

0 Comments